Valenza, C. et al. Circulating tumor DNA clearance as a predictive biomarker of pathologic complete response in patients with solid tumors treated with neoadjuvant immune checkpoint inhibitors: a systematic review and meta-analysis. Ann. Oncol. 36, 726–736 (2025).

Article  CAS  PubMed  Google Scholar 

Lam, W. K. J. et al. Achieving control of nasopharyngeal carcinoma: the role of Epstein-Barr virus-based screening and vaccines. Nat. Rev. Clin. Oncol. 23, 7–21 (2026).

Article  PubMed  Google Scholar 

Lv, J. et al. Risk-adaptive therapy guided by dynamic ctDNA in nasopharyngeal carcinoma. Nature 652, 731–739 (2026).

Article  PubMed  Google Scholar 

Liu, X. et al. Induction-concurrent chemoradiotherapy with or without sintilimab in patients with locoregionally advanced nasopharyngeal carcinoma in China (CONTINUUM): a multicentre, open-label, parallel-group, randomised, controlled, phase 3 trial. Lancet 403, 2720–2731 (2024).

Article  CAS  PubMed  Google Scholar 

Chen, Y. P. et al. Metronomic capecitabine as adjuvant therapy in locoregionally advanced nasopharyngeal carcinoma: a multicentre, open-label, parallel-group, randomised, controlled, phase 3 trial. Lancet 398, 303–313 (2021).

Article  CAS  PubMed  Google Scholar 

Le, Q. T. et al. An international collaboration to harmonize the quantitative plasma Epstein-Barr virus DNA assay for future biomarker-guided trials in nasopharyngeal carcinoma. Clin. Cancer Res. 19, 2208–2215 (2013).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chan, A. T. C. et al. Plasma Epstein-Barr virus DNA and residual disease after radiotherapy for undifferentiated nasopharyngeal carcinoma. J. Natl Cancer Inst. 94, 1614–1619 (2002).

Article  CAS  PubMed  Google Scholar 

Petit, C. et al. Role of chemotherapy in patients with nasopharynx carcinoma treated with radiotherapy (MAC-NPC): an updated individual patient data network meta-analysis. Lancet Oncol. 24, 611–623 (2023).

Article  CAS  PubMed  Google Scholar 

Chan, A. T. C. et al. Analysis of plasma Epstein-Barr virus DNA in nasopharyngeal cancer after chemoradiation to identify high-risk patients for adjuvant chemotherapy: a randomized controlled trial. J. Clin. Oncol. 36, 3091–3100 (2018).

Article  CAS  Google Scholar 

Chan, D. C. T. et al. Improved risk stratification of nasopharyngeal cancer by targeted sequencing of Epstein-Barr virus DNA in post-treatment plasma. Ann. Oncol. 33, 794–803 (2022).

Article  CAS  PubMed  Google Scholar